ECOG 2205: Title: A Phase II Study to Measure Response Rate and Toxicity of Neo-adjuvant Chemoradiotherapy with Oxaliplatin (OX) and Infusional 5-Fluorouracil (5-FU) Plus Cetuximab Followed by Post-operative Docetaxel and Cetuximab in Patients with Operable Adenocarcinoma of the Esophagus.

Trial Profile

ECOG 2205: Title: A Phase II Study to Measure Response Rate and Toxicity of Neo-adjuvant Chemoradiotherapy with Oxaliplatin (OX) and Infusional 5-Fluorouracil (5-FU) Plus Cetuximab Followed by Post-operative Docetaxel and Cetuximab in Patients with Operable Adenocarcinoma of the Esophagus.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Jan 2017

At a glance

  • Drugs Cetuximab (Primary) ; Docetaxel; Fluorouracil; Oxaliplatin
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Acronyms E2205
  • Most Recent Events

    • 21 Jan 2017 Results presented at the 2017 Gastrointestinal Cancers Symposium
    • 30 Jun 2009 New source identified and integrated (New Jersey Cancer Trial Connect)
    • 30 Jun 2009 Additional lead trial investigator identified as reported by New Jersey Cancer Trial Connect
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top